Why Replimune (REPL) Is Up 15.5% After Supportive FDA Panel Vote On IGNYTE Melanoma Data Simply Wall St 13h
STAT Plus: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more STAT 2d
FDA advisers dismiss safety warnings, back 4 peptide treatments Dermatology Advisor 5d Pharma Health All sources
FDA says Mantralaya canteen 98% clean, Bombay High Court orders lawyers' inspection India Today 2d Mumbai India Indian Politics All sources
FDA advisory committee votes against Deramiocel for DMD Cardiomyopathy Rare Disease Advisor 1d Duchenne Capricor Therapeutics Pharma All sources
Adcomm backs Replimune melanoma drug, despite data concern pharmaphorum 2d Replimune Cancer Treatment Pharma All sources
Medicare’s GLP-1 bridge program offers access, but isn’t straightforward Forbes 9h Donald Trump Novo Nordisk Medicare
Apnimed rises on its public debut as more drug developers prepare IPO launches Scrip Pharma Intelligence 1d
New non-opioid analgesic works better than Vicodin Pain News Network 1d Opioid Crisis Health Lifestyle
Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s Labiotech 2d Biotechnology Pharma
Amgen says cloud data breach exposed patient health, proprietary info BleepingComputer.com 1d Amgen Pharma Tech
Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline Business Wire (Press Release) 2d New Jersey Business Biotechnology Tech
